Phase 3
Completed N=182
Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia
Source: ClinicalTrials.gov NCT05270863 ↗Enrolled (actual)
182
Serious AEs
0.2%
Results posted
Sep 2024
Primary outcomePrimary: Proportion of Subjects With >=15 Letter Gain Without >=5 Letter Loss in Near Visual Acuity — 49.4; 35.0; 22.7 Percentage of participants — p=<.001
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Proportion of Subjects With >=15 Letter Gain Without >=5 Letter Loss in Near Visual Acuity |
49.4; 35.0; 22.7 | <.001 sig |
Eligibility Criteria
Inclusion Criteria
- Male or female in good general health
- Must have presbyopia
Exclusion Criteria
- History of allergic reaction to the study drug or any of its components
- Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results
Data sourced from ClinicalTrials.gov (NCT05270863). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.